

Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

NCT06591793

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	AAVantgarde Bio Srl
Enrollment	15 participants

Key Eligibility Criteria

Inclusion (2)

- Molecular diagnosis of USB1B due to MYO7A mutation
- Willingness to adhere to protocol per informed consent

Exclusion (5)

- Unwillingness to meet the requirements of the study
- Participation in a clinical study with an Investigation Product in the past 6 months
- Previous participation in another Gene Therapy trial
- Any condition that would preclude subretinal surgery
- Complicating ocular and/or systemic diseases

Locations (3 total)

University of Campania Luigi Vanvitelli, Naples, Italy
Moorfields Eye Hospital, London, United Kingdom
Retina Clinic London, London, United Kingdom